#USA #San Francisco #Biologics #Benchling #Antibody Research

Benchling Biologics: A Game-Changer in Antibody Research and Development

In the realm of biotechnology, the efficiency of research and development (R&D) processes can significantly impact the success of drug discovery. Benchling Biologics recently introduced a revolutionary end-to-end platform at the PEGS Boston Summit, aiming to streamline antibody R&D. This no-code solution allows scientists to configure various antibody formats swiftly and register an impressive number of antibodies in a single run, positioning itself as a necessary tool for modern biopharma labs.

The Introduction of Benchling Biologics

Launched in May 2026, Benchling Biologics addresses the challenges faced by antibody R&D teams. By offering a solution that allows scientists to handle complex protein data without extensive coding skills, the platform opens doors for faster configurations and automated registrations. According to Derek Halliday, Head of Product at Benchling, this innovation enables teams to expedite their R&D processes, replacing weeks of necessary waiting with mere minutes for format definitions and immediate registration of proteins.

Key Features of the Benchling Biologics Platform

Benchling Biologics provides several key features that cater specifically to the needs of R&D scientists. Here's how this platform revamps the workflow:

No-Code Antibody Configuration

Scientists can define intricate antibody formats and configurations almost instantaneously, a feat unachievable with traditional systems that often require specialized engineering support. With modular building blocks at their disposal, users can quickly adapt their workflow to suit evolving requirements, which is crucial as antibody design moves towards more complex structures, including bispecifics and multispecifics.

Streamlined Registration Process

Gone are the days when registering antibody constructs meant laboriously entering data. The Benchling Biologics platform provides an automated system that characterizes each entity and validates the data in real time. Whether it’s for CDR/FR regions, germline gene identification, or liability detection, Benchling ensures that the data collected during registration is not only comprehensive but also structured and linked to the experimental context.

Integrated Workflow for Enhanced Collaboration

The connected nature of Benchling Biologics offers a consolidated view of every aspect of antibody development. Scientists can track the progression of proteins from cloning to purification in a single workflow. Moreover, those utilizing automated laboratory systems benefit from direct integration, minimizing data transfer mishaps and enhancing reproducibility in experiments. If research necessitates outsourcing, the platform enables seamless order placements for biological materials, ensuring every output is closely tied to its respective design.

Closing the Learning Loop

An important feature of Benchling Biologics is its capability to close the loop on experiments. As results come in, they are immediately contextualized alongside the associated antibodies. This linkage between experimental data, sequences, and results remains intact throughout the R&D process, granting teams access to a consolidated record from design initiation to candidate selection. Furthermore, Benchling AI assists in summarizing insights and offering options for future designs, bringing in an element of predictive analysis that enhances the decision-making process.

Adoption and Future Prospects

Benchling Biologics is not only game-changing in functionality, but it also has the potential to accelerate the pace at which new therapies are developed. With over 1,300 companies relying on Benchling's platform—including industry giants like Merck and Moderna—this tool proves that speed and accuracy in biopharma workflows can be achieved concurrently.

As companies around the world evolve in their capabilities and become increasingly reliant on technology in their R&D efforts, Benchling Biologics stands at the forefront of this transformation. By empowering antibody R&D teams with an AI-ready data foundation, Benchling is set to redefine the future landscape of biologics, ensuring that innovative treatments reach the patients who need them faster than ever before.

Join the upcoming webinar on June 11 to explore Benchling Biologics in action, and witness first-hand how this platform is advancing antibody research into a more efficient future.